Display options
Cite
Kobayashi T, Furusawa Y, Yamada S, et al. Positron emission tomography to elucidate pharmacokinetic differences of regioisomeric retinoid x receptor agonists. ACS Med Chem Lett. 2015;6(3):334-8doi: 10.1021/ml500511m.
Kobayashi, T., Furusawa, Y., Yamada, S., Akehi, M., Takenaka, F., Sasaki, T., Akahoshi, A., Hanada, T., Matsuura, E., Hirano, H., Tai, A., & Kakuta, H. (2015). Positron emission tomography to elucidate pharmacokinetic differences of regioisomeric retinoid x receptor agonists. ACS medicinal chemistry letters, 6(3), 334-8. https://doi.org/10.1021/ml500511m
Kobayashi, Toshiki, et al. "Positron emission tomography to elucidate pharmacokinetic differences of regioisomeric retinoid x receptor agonists." ACS medicinal chemistry letters vol. 6,3 (2015): 334-8. doi: https://doi.org/10.1021/ml500511m
Kobayashi T, Furusawa Y, Yamada S, Akehi M, Takenaka F, Sasaki T, Akahoshi A, Hanada T, Matsuura E, Hirano H, Tai A, Kakuta H. Positron emission tomography to elucidate pharmacokinetic differences of regioisomeric retinoid x receptor agonists. ACS Med Chem Lett. 2015 Jan 20;6(3):334-8. doi: 10.1021/ml500511m. eCollection 2015 Mar 12. PMID: 25815156; PMCID: PMC4360156.
Copy Download .nbib Format: NLM
Share it on

ACS Med Chem Lett. 2015 Jan 20;6(3):334-8. doi: 10.1021/ml500511m. eCollection 2015 Mar 12.

Positron emission tomography to elucidate pharmacokinetic differences of regioisomeric retinoid x receptor agonists.

ACS medicinal chemistry letters

Toshiki Kobayashi, Yuki Furusawa, Shoya Yamada, Masaru Akehi, Fumiaki Takenaka, Takanori Sasaki, Akiya Akahoshi, Takahisa Hanada, Eiji Matsuura, Hiroyuki Hirano, Akihiro Tai, Hiroki Kakuta

Affiliations

  1. Division of Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , 1-1-1, Tsushima-Naka, Kita-ku, Okayama 700-8530, Japan.
  2. Division of Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , 1-1-1, Tsushima-Naka, Kita-ku, Okayama 700-8530, Japan ; Research Fellowship Division, Japan Society for the Promotion of Science , Sumitomo-Ichibancho FS Bldg., 8 Ichibancho, Chiyoda-ku, Tokyo 102-8472, Japan.
  3. Collaborative Research Center for OMIC, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , 2-5-1 Shikata-Cho, Kita-ku, Okayama 700-8558, Japan.
  4. SHI Accelerator Service Ltd. 1-17-6 Osaki, Shinagawa-ku, Tokyo 141-0032, Japan.
  5. Faculty of Life and Environmental Sciences, Prefectural University of Hiroshima , 562 Nanatsuka-Cho, Shobara, Hiroshima 727-0023, Japan.

PMID: 25815156 PMCID: PMC4360156 DOI: 10.1021/ml500511m

Abstract

RXR partial agonist NEt-4IB (2a, 6-[ethyl-(4-isobutoxy-3-isopropylphenyl)amino]pyridine-3-carboxylic acid: EC50 = 169 nM, E max = 55%) showed a blood concentration higher than its E max after single oral administration at 30 mg/kg to mice, and repeated oral administration at 10 mg/kg/day to KK-A(y) mice afforded antitype 2 diabetes activity without the side effects caused by RXR full agonists. However, RXR full agonist NEt-3IB (1a), in which the isobutoxy and isopropyl groups of 2a are interchanged, gave a much lower blood concentration than 2a. Here we used positron emission tomography (PET) with tracers [(11)C]1a, [(11)C]2a and fluorinated derivatives [(18)F]1b, [(18)F]2b, which have longer half-lives, to examine the reason why 1a and 2a exhibited significantly different blood concentrations. As a result, the reason for the high blood concentration of 2a after oral administration was found to be linked to higher intestinal absorbability together with lower biliary excretion, compared with 1a.

Keywords: Nuclear receptors; PET imaging; RXR; pharmacokinetics

References

  1. Eur J Clin Pharmacol. 2003 Sep;59(5-6):357-66 - PubMed
  2. Nature. 1997 Mar 27;386(6623):407-10 - PubMed
  3. Immunotherapy. 2013 Apr;5(4):427-33 - PubMed
  4. ACS Med Chem Lett. 2014 Feb 27;5(6):668-72 - PubMed
  5. Science. 2013 May 24;340(6135):924-g - PubMed
  6. Clin Lymphoma. 2003 Mar;3(4):249-52 - PubMed
  7. Biochem Pharmacol. 2001 Dec 1;62(11):1501-9 - PubMed
  8. J Nucl Med. 1986 Feb;27(2):235-8 - PubMed
  9. ChemMedChem. 2008 May;3(5):780-7 - PubMed
  10. Science. 2012 Mar 23;335(6075):1503-6 - PubMed
  11. Bioorg Med Chem. 2005 Mar 1;13(5):1579-86 - PubMed
  12. Diabetologia. 1999 May;42(5):545-54 - PubMed
  13. Clin Pharmacokinet. 2002;41(8):581-602 - PubMed
  14. ACS Med Chem Lett. 2010 Aug 27;1(9):521-5 - PubMed
  15. J Med Chem. 2015 Jan 22;58(2):912-26 - PubMed
  16. Chembiochem. 2004 May 3;5(5):637-43 - PubMed
  17. Endocrinology. 2009 May;150(5):2368-75 - PubMed
  18. Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26 - PubMed
  19. ACS Chem Neurosci. 2013 Nov 20;4(11):1430-8 - PubMed
  20. Biochem Pharmacol. 1997 Aug 15;54(4):517-24 - PubMed
  21. J Nucl Med. 2011 Feb;52(2):249-56 - PubMed

Publication Types